

Rs in lakhs (except for number of shares)

Statement of audited results for the quarter and year ended 31 March 2013						
Part I	Particulars	3 months ended 31/03/2013	3 months ended 31/12/2012	3 months ended 31/03/2012	Year ended 31/03/2013	Previous year ended 31/03/2012
Sl No.		(Audited) ²	(Unaudited)	(Audited) ²	(Audited)	(Audited)
1	Income from operations					
	a) Net sales/ income from operations (net of excise duty)	9,485.13	10,491.39	9,168.98	39,025.42	53,127.97
	b) Other operating income	6.52	2.49	9.70	16.68	24.05
	Total income from operations (net)	9,491.65	10,493.88	9,178.68	39,042.10	53,152.02
2	Expenses					
	(a) Cost of materials consumed	1,454.65	947.74	1,409.45	4,497.53	7,151.68
	(b) Purchase of stock-in-trade	3,039.64	3,071.44	834.28	11,163.77	11,923.13
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,383.90)	20.06	2,216.16	(347.91)	(1,210.38)
	(d) Employee benefits expense	3,681.98	3,965.48	5,791.09	14,846.02	16,191.24
	(e) Depreciation and amortisation expense	548.36	254.01	181.03	1,227.82	733.86
	(f) Other expenses	4,075.66	4,026.31	3,843.76	15,728.17	16,070.05
	Total expenses	11,416.39	12,285.04	14,275.77	47,115.40	50,859.58
3	Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)	(1,924.74)	(1,791.16)	(5,097.09)	(8,073.30)	2,292.44
4	Other income	67.21	21.63	201.41	1,046.29	633.04
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	(1,857.53)	(1,769.53)	(4,895.68)	(7,027.01)	2,925.48
6	Finance costs	-	-	-	-	-
7	Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)	(1,857.53)	(1,769.53)	(4,895.68)	(7,027.01)	2,925.48
8	Exceptional items	-	-	-	-	-
9	Profit/ (loss) from ordinary activities before tax (7+8)	(1,857.53)	(1,769.53)	(4,895.68)	(7,027.01)	2,925.48
10	Tax expense	-	-	(1,595.23)	1,926.23	948.97
11	Net profit/(loss) from ordinary activities after tax (9-10)	(1,857.53)	(1,769.53)	(3,300.45)	(8,953.24)	1,976.51
12	Extraordinary Item	-	-	-	-	-
13	Net profit/(loss) for the period (11-12)	(1,857.53)	(1,769.53)	(3,300.45)	(8,953.24)	1,976.51
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year				9,475.29	18,428.52
16	Basic and diluted earnings (Rs) per share (not annualised)	(7.43)	(7.08)	(13.20)	(35.81)	7.91


Select information for the year ended 31 March 2013						
Part II	Particulars	3 months ended 31/03/2013	3 months ended 31/12/2012	3 months ended 31/03/2012	Year ended 31/03/2013	Previous year ended 31/03/2012
A	Particulars of shareholding					
1	Public shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
2	Promoters and promoter group shareholding					
	a) Pledged/Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%

B.	Particulars	3 months ended 31/03/2013
	Investor complaints	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	1
	Disposed of during the quarter	1
	Remaining unresolved at the end of the quarter	Nil

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 21 May 2013.
- Figures for the 3 months ended 31 March 2013 and 31 March 2012 are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto the third quarter of the respective financial year. Also, the figures upto the period ended 31 December 2012 and 31 December 2011 were only reviewed and not subjected to audit.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion.
- Other income for the year ended 31 March 2013 includes an amount of Rs 693.49 lakhs towards compensation for factory land acquired by National Highway Authority of India during the financial year 2011-12.
- At the end of the financial year 2011-12, the factory experienced interruptions to the supply of certain products. The Company has invested, and continues to invest, resources to remediate these interruptions. As a result of the remediation being carried out, the Company has succeeded in gradually returning a majority of the products to the market. Revenues and the financial results for the current year ended 31 March 2013 were thus impacted.
- Tax expense represents deferred tax assets amounting to Rs 2,429.97 lacs which have been charged to the profit and loss for the year ended 31 March 2013.
- Following the submission to the Stock Exchanges of the unaudited financial results for the quarter ended 31 March 2013 on 2nd May 2013, (a) an application seeking approval of the Central Government to the appointment of Mr Robert Ian Haxton as Wholtime Director has been filed by the Company and (b) approval of the shareholders in general meeting by a special resolution pursuant to the applicable provisions of Schedule XIII to the Companies Act, 1956 for his appointment as Wholtime Director and for the payment of remuneration to him will be sought at the ensuing Annual General Meeting.
- Following the submission to the Stock Exchanges of the unaudited financial results for the quarter ended 31 March 2013 on 2nd May 2013, the approval of the shareholders in general meeting by a special resolution pursuant to the applicable provisions of Schedule XIII to the Companies Act, 1956 for the remuneration paid to Mr Anandh Balasundaram, the former Managing Director and Ms Ruby Lau, the former Whole Time Director will be sought at the ensuing Annual General Meeting.
- The statutory auditors have issued an unqualified audit report. The audit report has been filed with the stock exchange and is also available on the Company's website.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Sanjay Murdesfiwer
Managing Director

AstraZeneca Pharma India Limited
Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

(Rs in lakhs)

Sl.no.	Particulars	3 months ended 31/03/2013	3 months ended 31/12/2012	3 months ended 31/03/2012	Year ended 31/03/2013	Previous year ended 31/03/2012
		(Audited) ²	(Unaudited)	(Audited) ²	(Audited)	(Audited)
1	Segment revenue					
	(a) Healthcare	8,535.62	9,463.99	8,303.82	35,586.81	49,977.92
	(b) Others	956.03	1,029.89	874.86	3,455.29	3,174.10
	Total	9,491.65	10,493.88	9,178.68	39,042.10	53,152.02
	Less: Inter-segment revenue	-	-	-	-	-
	Net income from operations	9,491.65	10,493.88	9,178.68	39,042.10	53,152.02
2	Segment results					
	Profit/(loss) before tax and interest					
	(a) Healthcare	(2,089.94)	(2,003.34)	(5,122.57)	(8,477.84)	2,165.28
	(b) Others	165.20	212.18	25.48	404.54	127.16
	Total	(1,924.74)	(1,791.16)	(5,097.09)	(8,073.30)	2,292.44
	Add: Other income	67.21	21.63	201.41	1,046.29	633.04
	Less: Interest	-	-	-	-	-
	Total profit/(loss) before tax	(1,857.53)	(1,769.53)	(4,895.68)	(7,027.01)	2,925.48
3	Capital employed					
	(a) Healthcare	6,929.46	8,217.69	11,722.25	6,929.46	11,722.25
	(b) Others	122.37	184.81	817.67	122.37	817.67
	(c) Unallocated	2,923.46	3,430.31	6,388.60	2,923.46	6,388.60
	Total	9,975.29	11,832.81	18,928.52	9,975.29	18,928.52

Notes :

- 1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- 2 Figures for the 3 months ended 31 March 2013 and 31 March 2012 are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto the third quarter of the respective financial year. Also, the figures upto the period ended 31 December 2012 and 31 December 2011 were only reviewed and not subjected to audit.

AstraZeneca Pharma India Limited
 Regd Office : "Avishkar" Off Bellary Road , Hebbal Bangalore - 560 024
 Statement of assets and liabilities

Sl.no.	Particulars	As at 31 March 2013 (Audited)	As at 31 March 2012 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	500.00	500.00
	(b) Reserves and Surplus	9,475.29	18,428.52
	(c) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	9,975.29	18,928.52
2	Share application money pending allotment	-	-
3	Non-current liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	48.94	54.44
	(d) Long-term provisions	-	-
	Sub-total - Non-current liabilities	48.94	54.44
4	Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	9,067.22	2,091.36
	(c) Other current liabilities	7,720.83	6,746.20
	(d) Short-term provisions	3,797.89	6,670.79
	Sub-total - Current liabilities	20,585.94	15,508.35
	TOTAL - EQUITY AND LIABILITIES	30,610.17	34,491.31
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	9,824.15	9,018.24
	(b) Non-current investments	0.57	0.57
	(c) Deferred tax assets (net)	-	1,776.23
	(d) Long-term loans and advances	3,472.78	3,997.67
	(e) Other non-current assets	831.60	240.03
	Sub-total - Non-current assets	14,129.10	15,032.74
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	8,536.91	7,509.69
	(c) Trade receivables	2,796.32	3,230.79
	(d) Cash and bank balances	1,846.86	5,321.96
	(e) Short-term loans and advances	2,033.21	2,306.26
	(f) Other current assets	1,267.77	1,089.87
	Sub-total - Current assets	16,481.07	19,458.57
	TOTAL - ASSETS	30,610.17	34,491.31